Natural Killer T Cell Diversity and Immunotherapy
Cancers · 07.12.2023 · 15 (24) · 5737
DOI: 10.3390/cancers15245737 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 07.12.2023. Verfasst von Eduardo I Tognarelli und 7 weiteren Autor:innen. Beteiligte Einrichtung: Millennium Institute on Immunology and Immunotherapy, Santiago 8330025, Chile. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 233 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencia Nacional de Investigación y Desarrollo, Puente UC, FONDECYT.
Abstract (Originalsprache)
Invariant natural killer T cells (iNKTs), a type of unconventional T cells, share features with NK cells and have an invariant T cell receptor (TCR), which recognizes lipid antigens loaded on CD1d molecules, a major histocompatibility complex class I (MHC-I)-like protein. This interaction produces the secretion of a wide array of cytokines by these cells, including interferon gamma (IFN-γ) and interleukin 4 (IL-4), allowing iNKTs to link innate with adaptive responses. Interestingly, molecules that bind CD1d have been identified that enable the modulation of these cells, highlighting their potential pro-inflammatory and immunosuppressive capacities, as required in different clinical settings. In this review, we summarize key features of iNKTs and current understandings of modulatory α-galactosylceramide (α-GalCer) variants, a model iNKT cell activator that can shift the outcome of adaptive immune responses. Furthermore, we discuss advances in the development of strategies that modulate these cells to target pathologies that are considerable healthcare burdens. Finally, we recapitulate findings supporting a role for iNKTs in infectious diseases and tumor immunotherapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Millennium Institute on Immunology and Immunotherapy, Santiago 8330025, Chile.
- Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago 8331150, Chile.
- Programa de Inmunología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, Santiago 8380453, Chile.
ORCID-Profile: Eduardo I Tognarelli, Cristián Gutiérrez-Vera, Pablo A Palacios, Fernanda Aguirre-Muñoz, Pablo A González
Förderung
- Agencia Nacional de Investigación y Desarrollo
- Puente UC
- FONDECYT
- FONDEF ANID
- Instituto Milenio en Inmunología e Inmunoterapia—Millennium Institute on Immunology and Immunotherapy ICM—ANID
- Chilean National Agency for Research and Development (ANID)/Scholarship Program/Doctorado Nacional/2020
- Chilean National Agency for Research and Development (ANID)/Scholarship Program/Doctorado Nacional/2021
Zitieren
APA
Tognarelli, E. I., Gutiérrez-Vera, C., Palacios, P. A., Pasten-Ferrada, I. A., Aguirre-Muñoz, F., Cornejo, D. A., González, P. A., & Carreño, L. J. (2023). Natural Killer T Cell Diversity and Immunotherapy. Cancers, 15(24), 5737. https://doi.org/10.3390/cancers15245737
Vancouver
Tognarelli EI, Gutiérrez-Vera C, Palacios PA, Pasten-Ferrada IA, Aguirre-Muñoz F, Cornejo DA, et al. Natural Killer T Cell Diversity and Immunotherapy. Cancers. 2023;15(24):5737. doi:10.3390/cancers15245737
BibTeX
@article{Tognarelli2023,
author = {Tognarelli, Eduardo I and Gutiérrez-Vera, Cristián and Palacios, Pablo A and Pasten-Ferrada, Ignacio A and Aguirre-Muñoz, Fernanda and Cornejo, Daniel A and González, Pablo A and Carreño, Leandro J},
title = {Natural Killer T Cell Diversity and Immunotherapy},
journal = {Cancers},
year = {2023},
volume = {15},
number = {24},
pages = {5737},
doi = {10.3390/cancers15245737}
}
EUVIMED